一年内定量CT变化与纤维化肺疾病有意义结局相关
本研究评估纤维化间质性肺疾病(fILD)患者一年内定量纤维化评分(DTA)变化与后续FVC及生存的关联。主要队列407例,DTA一年内增加与后续FVC下降和无移植生存率降低相关,最大效应见于基线DTA低者,验证队列证实。DTA变化可能作为试验终点、队列富集工具和临床护理指标。
要点
- 一年内DTA增加与后续FVC下降及无移植生存率降低独立相关。
- 基线DTA低者中,DTA一年增加5%对应FVC年降-91 ml(95%CI -117,-65),大于稳定DTA者的-49 ml(95%CI -69,-29)。
- DTA一年增加5%的无移植生存风险比为1.45(95%CI 1.25,1.68),验证队列结果一致。
核心结论
- fILD患者一年内DTA评分变化与未来疾病轨迹及无移植生存相关。
- DTA可作为试验终点、队列富集工具并纳入临床护理的指标。
研究设计与样本
- 主要队列纳入2017至2020年评估的fILD患者407例,中位年龄70.5岁(IQR 64.8,75.9),男性214例,均有基线和1年随访HRCT及FVC。
- 采用线性混合模型评估DTA变化与后续FVC的关联,Cox比例风险模型评估无移植生存。
- 肺纤维化基金会患者注册库作为验证队列。
主要发现
- DTA一年内增加与后续FVC下降和无移植生存率降低相关。
- 基线DTA低者中,DTA一年增加5%对应FVC年变化-91 ml(95%CI -117,-65),稳定DTA者为-49 ml/yr(95%CI -69,-29),P=0.0002。
- DTA一年增加5%的无移植生存风险比为1.45(95%CI 1.25,1.68)。
- 验证队列证实上述发现。
临床怎么用
- 可将一年内DTA变化纳入fILD患者临床评估,辅助判断疾病进展风险。
- DTA变化可作为临床试验终点和富集高危人群的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Whether change in fibrosis on high-resolution computed tomography is associated with near- and longer-term outcomes in patients with fibrotic interstitial lung disease (fILD) remains unclear. Objectives: We evaluated the association between 1-year change in quantitative fibrosis scores (data-driven textural analysis [DTA]) and subsequent FVC and survival in patients with fILD. Methods: The primary cohort included patients with fILD evaluated from 2017 to 2020 with baseline and 1-year follow-up high-resolution computed tomography and FVC. Associations between DTA change and subsequent FVC were assessed using linear mixed models. Transplant-free survival was assessed using Cox proportional hazards models. The Pulmonary Fibrosis Foundation Patient Registry served as the validation cohort. Measurements and Main Results: The primary cohort included 407 patients (median [interquartile range] age, 70.5 [64.8, 75.9] yr; 214 male). One-year increase in DTA was associated with subsequent FVC decline and transplant-free survival. The largest effect on FVC was observed in patients with low baseline DTA scores, in whom a 5% increase in DTA over 1 year was associated with a change in FVC of -91 ml/yr (95% confidence interval [CI], -117, -65 vs. stable DTA, -49 ml/yr; 95% CI, -69, -29; P = 0.0002). The hazard ratio for transplant-free survival for a 5% increase in DTA over 1 year was 1.45 (95% CI, 1.25, 1.68). The findings were confirmed in the validation cohort. Conclusions: One-year change in DTA score is associated with future disease trajectory and transplant-free survival in patients with fILD. DTA could be a useful trial endpoint, cohort enrichment tool, and metric to incorporate into clinical care.
引用
- Koslow M, Baraghoshi D, Swigris JJ, et al. One-Year Change in Quantitative Computed Tomography Is Associated with Meaningful Outcomes in Fibrotic Lung Disease. Am J Respir Crit Care Med. 2025. PMID: 40824122. doi:10.1164/rccm.202503-0535OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。